Prosecution Insights
Prosecution Insights
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (67%) |
| No statute on record | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SAOUD, CHRISTINE J | 1 | 57.8% | +37.9% |
| SHIM, DAVID M. | 1 | 58.8% | +56.0% |
| MOEHLMAN, ANDREW TERRY | 1 | 67.4% | +62.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18491616 | LONG-ACTING FGF21 FUSION PROTEINS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | SAOUD, CHRISTINE J | 10d overdue |
| 18273888 | METHODS FOR PURIFYING AN ANTI-4-1BB/ANTI-HER2 BISPECIFIC ANTIBODY | MOEHLMAN, ANDREW TERRY | 14d |
| 18551894 | NOVEL INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS, PROCESSES FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | SHIM, DAVID M. | 27d |
| Art Unit | Apps |
|---|---|
| 1645 | 1 |
| 1626 | 1 |
| 1655 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18491616 | LONG-ACTING FGF21 FUSION PROTEINS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | SAOUD, CHRISTINE J | 1645 | Other | Non-Final OA | 10d overdue | Pending | Oct 20, 2023 |
| 18551894 | NOVEL INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS, PROCESSES FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | SHIM, DAVID M. | 1626 | §103 | Non-Final OA | 27d | Pending | Sep 22, 2023 |
| 18273888 | METHODS FOR PURIFYING AN ANTI-4-1BB/ANTI-HER2 BISPECIFIC ANTIBODY | MOEHLMAN, ANDREW TERRY | 1655 | §103 | Non-Final OA | 14d | Pending | Jul 24, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial